Jun 14, 2026Metabolic Therapeutics

Tirzepatide vs. Semaglutide: More Fat Loss, Not Proven Appetite Edge

A 28-week head-to-head trial found greater weight and fat loss with tirzepatide than semaglutide 1 mg—but appetite superiority remains unproven.

tirzepatidesemaglutideweight losstype 2 diabetes

Read article →

Mar 29, 2026Cardiometabolic Health

GLP-1 Drugs and PAD: Better Walking, Unproven Amputation Prevention

GLP-1 drugs may improve walking in diabetes and PAD, but the headline 47% amputation reduction comes from weak observational evidence—not trials.

glp-1 agonistssemaglutideliraglutideperipheral artery disease

Read article →

Mar 27, 2026Cardiovascular Health

GLP-1 Drugs and Heart Failure: What an NNT of 80 Means

GLP-1 drugs reduce heart failure events modestly overall, with stronger signals in obesity. See what the NNTs, limits, and next-generation drugs mean.

glp-1 agonistssemaglutidetirzepatideheart failure

Read article →

Mar 27, 2026Nutrition

Oral Semaglutide and Fatty Liver: What a 28-Week Trial Shows

Can oral semaglutide help fatty liver disease? A 28-week obesity trial found weight loss and lower liver stiffness, but fibrosis evidence remains incomplete.

semaglutideglp-1liver fibrosisnafld

Read article →

Mar 26, 2026Body Composition

GLP-1 Weight Loss: How Much Is Lean Mass?

A 2026 meta-analysis compares lean-mass loss on semaglutide, tirzepatide, and dieting—and shows why resistance training matters most.

semaglutidetirzepatideglp-1 agonistslean mass loss

Read article →

Mar 26, 2026Pharmacotherapy

SGLT2 vs GLP-1 Heart Protection Changes With Age

A large diabetes meta-analysis finds age may shift the relative heart benefit of SGLT2 inhibitors and GLP-1 drugs, while sex does not.

ozempicglp-1 agonistssglt2 inhibitorscardiovascular outcomes

Read article →

Mar 22, 2026Neuroprotection

Do GLP-1 Drugs Protect the Brain? The Evidence So Far

Do semaglutide and other GLP-1 drugs lower Parkinson's or Alzheimer's risk? Examine the observational signals, bias tests, and missing trial data.

glp-1 agonistssemaglutideparkinson's diseasealzheimer's disease

Read article →

Mar 21, 2026Metabolic Drugs

GLP-1 Heart Benefits: Blood Pressure Matters, But So Does Weight

GLP-1 drugs cut major cardiovascular events. Ambulatory monitoring suggests blood pressure gets more credit—but weight and direct effects still matter.

glp-1 agonistssemaglutideblood pressurecardiovascular outcomes

Read article →

Mar 21, 2026Cardiovascular Health

GLP-1 Drugs and Stroke: What the Evidence Actually Shows

Do GLP-1 drugs lower stroke risk? Randomized trials show fewer ischemic strokes in high-risk type 2 diabetes, while hemorrhagic and obesity data remain uncertain.

glp-1semaglutideischemic strokecardiovascular outcomes

Read article →

Mar 21, 2026Mental Health

GLP-1 Drugs and Vascular Dementia: A Signal, Not Proof

GLP-1 receptor agonists may reduce vascular dementia risk, but randomized evidence remains imprecise. What the stroke data and cohorts actually show.

glp-1semaglutidevascular dementiaozempic

Read article →

Mar 21, 2026Medication Safety

Do GLP-1 Drugs Raise Suicide Risk? What Trials Show

FDA and EMA reviews raised alarm about GLP-1 drugs and suicide. Placebo-controlled trials find no increased risk, but key gaps remain.

glp-1 agonistssemaglutidesuicidal ideationozempic

Read article →

Mar 21, 2026Glp 1 Agonists

47 GLP-1 Trials: What the Pooled Weight-Loss Result Means

A 47-trial GLP-1 meta-analysis found lower weight, BMI, and waist size—but pooled results hide major differences by drug and diabetes status.

tirzepatidesemaglutideglp-1 agonistliraglutide

Read article →

Page 1 of 3Next →